title: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
abstract: Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia. However, what makes an antipsychotic 'atypical' remains unclear. We recently found that the T102C polymorphism in the 5-HT2A receptor gene could affect risperidone's efficacy for negative symptoms. The present study investigated the effect of the Ser311Cys polymorphism in the dopamine D2 receptor (DRD2) gene on risperidone treatment response. A total of 123 Han Chinese patients with acutely exacerbated schizophrenia were given risperidone for up to 42 days. Clinical manifestations were measured bi-weekly with Positive and Negative Syndrome Scale (PANSS) and Nurses' Observation Scale for Inpatients Evaluation (NOSIE, for assessment of social function). For adjusting the within-subject dependence over repeated assessments, multiple linear regression with generalized estimating equation methods was utilized to analyse the effects of Ser311Cys polymorphism and other covariates on clinical performance. Compared with patients who had the Ser311Ser genotype, patients with the Ser311Cys genotype had lower scores on PANSS Positive, Negative, General Psychopathology and Cognitive subscales and NOSIE, after adjustment for 5-HT2A T102C polymorphisms and other confounders. The 5-HT2A T102C polymorphism had marginal influences on PANSS Total and Negative subscale scores. Male gender, fewer previous hospitalizations, and higher risperidone dose predicted better treatment response after control for other variables. The preliminary results suggest that variations in the DRD2 gene influence risperidone treatment response for positive, negative, and cognitive symptoms, general psychopathology, and social functioning. Several clinical factors may also contribute to inter-individual differences in risperidone treatment response.
authors.affiliation: Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan, ROC. hylane@pchome.com.tw
authors.forename: Hsien-Yuan
authors.initials: HY
authors.lastname: Lane
authors.forename: Cheng-Chun
authors.initials: CC
authors.lastname: Lee
authors.forename: Yue-Cune
authors.initials: YC
authors.lastname: Chang
authors.forename: Chung-Ta
authors.initials: CT
authors.lastname: Lu
authors.forename: Chiung-Hsien
authors.initials: CH
authors.lastname: Huang
authors.forename: Wen-Ho
authors.initials: WH
authors.lastname: Chang
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D005838:Genotype; D006801:Humans; D007206:Individuality; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D018967:Risperidone / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012919:Social Behavior
chemical_list: D014150:Antipsychotic Agents; D017448:Receptors, Dopamine D2; D018967:Risperidone